Clik here to view.
Sanofi makes $1.2B deal with Novavax on Covid vaccine, explores flu combinations
Sanofi is handing Novavax $500 million upfront to bring the biotech’s Covid-19 vaccine into the fold, with dual goals of co-commercializing the current vaccine and developing combo vaccines that can...
View ArticleClik here to view.
FDA delays Moderna RSV vaccine decision, but what's next is likely to be a...
The FDA has delayed the PDUFA date for Moderna’s RSV vaccine, the company announced Friday morning. The delay likely won’t push the decision past the end of May, according to Moderna’s press release,...
View ArticleClik here to view.
Lykos shores up commercial team for MDMA drug; Former J&J CEO Alex Gorsky...
Allison Rosenthal Lykos Therapeutics is on a journey to get the first MDMA-assisted PTSD therapy approved by the FDA, and the biotech has tapped two new leaders to complete the trip. The additions of...
View ArticleMacroGenics investigates three patient deaths in Phase 2 prostate cancer drug...
MacroGenics reported on Thursday afternoon that three patients died in a mid-stage trial of its antibody-drug conjugate for prostate cancer. Two participants died due to pneumonitis and the third died...
View ArticleClik here to view.
Tessera unveils promising in vivo gene editing treatment for sickle cell in...
Tessera Therapeutics, a well-funded startup based outside of Boston, announced Friday that it developed a lipid nanoparticle that shuttles a gene editing therapy directly to the bone marrow of mice....
View ArticleClik here to view.
Ginkgo to cut spending, lay off staff after earnings disappointment
Ginkgo Bioworks is looking to cut expenses and personnel in an effort to return to profitability and break even by the end of 2026. The company said it is planning to reduce operating expenses —...
View ArticleiTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
Plus, news about AnaptysBio, Alzamend, AEON Biopharma and argenx: iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital...
View ArticleClik here to view.
Scientists and startups reveal new gene insertion techniques, though much...
Several secretive and well-funded biotechs are sharing the first glimpses of data from a new suite of gene editing tools that promise to overcome one of the field’s grand challenges: precisely...
View ArticleExcision BioTherapeutics’ attempt to gene edit HIV disappoints. The company...
BALTIMORE — HIV patients who received a CRISPR-based gene editing treatment developed by Excision BioTherapeutics saw the virus rebound, and now the company is going back to the lab to develop the...
View ArticleHouse Republicans put pressure on ASPR’s management of the national drug...
Lawmakers in the House Energy and Commerce Committee criticized the management of the national stockpile in a letter to the federal government’s Administration for Strategic Preparedness and Response...
View ArticleSenators question Chamber of Commerce's motives around march-in rights
Sens. Elizabeth Warren (D-MA), Bernie Sanders (I-VT) and Jeff Merkley (D-OR) accused a new US Chamber of Commerce coalition of attempting to “stymie the White House’s drug pricing initiatives.” The...
View ArticleNew Biosecure draft features 2032 grandfather clause, five-year grace period...
Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an updated draft of the closely watched Biosecure Act circulating ahead of the...
View ArticleTop stories from cell/gene therapy confab; 2032 deadline to decouple; Patient...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleSanofi, Pfizer, AstraZeneca, GSK to invest €2B+ in R&D, manufacturing in France
Sanofi, Pfizer and AstraZeneca separately pledged to increase their footprint in France, with investments adding up to almost €2 billion. GSK, AbbVie and Novartis are also allocating money to expand...
View ArticleClik here to view.
Sanofi buys ex-US rights to Fulcrum's Phase 3 rare neuromuscular drug
Sanofi will pay $80 million upfront to snag the ex-US license to Fulcrum Therapeutics’ rare neuromuscular disease treatment candidate, which will have Phase 3 data in the fourth quarter and potential...
View ArticleClik here to view.
Trailblazers, iconoclasts and breakthrough artists are coming to the...
Aviv Regev When Aviv Regev closed out one long chapter of her life at the Broad and stepped into a new job as head of research and early development at Genentech four years ago, she set out to build a...
View ArticleAjax gets $95M to test new JAK2 inhibitor after industry's series of...
A large pharma company wanted to buy Ajax Therapeutics when it was raising a $40 million Series B in 2021. But the startup thought it could do better on its own. “We thought that the compound at the...
View ArticleNewVale unveils $167M fund to back pharma service providers and 'old ideas...
Growth equity firm NewVale Capital officially broke cover with its $167 million fund on Monday morning to back third-party service providers that support the drug development industry. The Boulder,...
View ArticleCarolyn Bertozzi-founded Lycia Therapeutics raises $106M to enter the clinic
A different take on protein degradation will enter human trials as Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, has refueled with $106.6 million. The Series C, disclosed Monday...
View ArticleClik here to view.
Takeda bets $100M upfront on AC Immune's anti-amyloid Alzheimer's vaccine
AC Immune has lined up its third pharma partner in Alzheimer’s disease, and the pact comes with a hefty biobucks package. Takeda will pay AC Immune $100 million upfront to snag the exclusive option to...
View Article